A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)

Trial Profile

A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms CIRCLE
  • Sponsors ThromboGenics
  • Most Recent Events

    • 11 May 2017 According to a ThromboGenics media release, recruitment has picked-up after protocol amendment in this trial.
    • 27 Dec 2016 Planned number of patients changed from 230 to 115.
    • 27 Dec 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top